Aarhus University Seal / Aarhus Universitets segl

Effects of long-term antipsychotics treatment on body weight: A population-based cohort study

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Standard

Effects of long-term antipsychotics treatment on body weight : A population-based cohort study. / Bazo-Alvarez, Juan Carlos; Morris, Tim P.; Carpenter, James R.; Hayes, Joseph F.; Petersen, Irene.

I: Journal of Psychopharmacology, Bind 34, Nr. 1, 01.2020, s. 79-85.

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Harvard

Bazo-Alvarez, JC, Morris, TP, Carpenter, JR, Hayes, JF & Petersen, I 2020, 'Effects of long-term antipsychotics treatment on body weight: A population-based cohort study', Journal of Psychopharmacology, bind 34, nr. 1, s. 79-85. https://doi.org/10.1177/0269881119885918

APA

Bazo-Alvarez, J. C., Morris, T. P., Carpenter, J. R., Hayes, J. F., & Petersen, I. (2020). Effects of long-term antipsychotics treatment on body weight: A population-based cohort study. Journal of Psychopharmacology, 34(1), 79-85. https://doi.org/10.1177/0269881119885918

CBE

Bazo-Alvarez JC, Morris TP, Carpenter JR, Hayes JF, Petersen I. 2020. Effects of long-term antipsychotics treatment on body weight: A population-based cohort study. Journal of Psychopharmacology. 34(1):79-85. https://doi.org/10.1177/0269881119885918

MLA

Vancouver

Bazo-Alvarez JC, Morris TP, Carpenter JR, Hayes JF, Petersen I. Effects of long-term antipsychotics treatment on body weight: A population-based cohort study. Journal of Psychopharmacology. 2020 jan;34(1):79-85. https://doi.org/10.1177/0269881119885918

Author

Bazo-Alvarez, Juan Carlos ; Morris, Tim P. ; Carpenter, James R. ; Hayes, Joseph F. ; Petersen, Irene. / Effects of long-term antipsychotics treatment on body weight : A population-based cohort study. I: Journal of Psychopharmacology. 2020 ; Bind 34, Nr. 1. s. 79-85.

Bibtex

@article{dc845c4cf2de450b80ca3e3bec887c0b,
title = "Effects of long-term antipsychotics treatment on body weight: A population-based cohort study",
abstract = "Background: Antipsychotics are often prescribed for long-term periods, however, most evidence of their impact on body weight comes from short-term clinical trials. Particularly, impact associated with dosage has been barely studied. Aims: The aim of this study was to describe the short- and long-term change in body weight of people initiated on high or low doses of the three most commonly prescribed second-generation antipsychotics. Methods: Retrospective cohorts of individuals with a diagnosed psychotic disorder observed from 2005 to 2015 in the UK primary care. The exposure was the first prescription of olanzapine, quetiapine or risperidone. The main outcome was change in body weight four years before and four years after initiation of antipsychotic treatment, stratified on sex and {\textquoteleft}low{\textquoteright} or {\textquoteleft}high{\textquoteright} dose. Results: In total, 22,306 women and 16,559 men were observed. Olanzapine treatment was associated with the highest change in weight, with higher doses resulting in more weight gain. After 4 years, given a high dose of olanzapine (> 5 mg), women gained on average +6.1 kg; whereas given a low dose (⩽ 5 mg), they gained +4.4 kg. During the first six weeks of olanzapine treatment, they gained on average +3.2 kg on high dose and +1.9 kg on low dose. The trends were similar for men. Individuals prescribed risperidone and quetiapine experienced less weight gain in both the short- and long-term. Conclusions: Olanzapine treatment was associated with the highest increase in weight. Higher doses were associated with more weight gain. Doctors should prescribe the lowest effective dose to balance mental-health benefits, weight gain and other adverse effects.",
keywords = "Antipsychotic agents, dopamine, electronic health records, interrupted time series analysis, noradrenaline, serotonin, weight gain",
author = "Bazo-Alvarez, {Juan Carlos} and Morris, {Tim P.} and Carpenter, {James R.} and Hayes, {Joseph F.} and Irene Petersen",
year = "2020",
month = jan,
doi = "10.1177/0269881119885918",
language = "English",
volume = "34",
pages = "79--85",
journal = "Journal of Psychopharmacology",
issn = "0269-8811",
publisher = ": SAGE Publications ",
number = "1",

}

RIS

TY - JOUR

T1 - Effects of long-term antipsychotics treatment on body weight

T2 - A population-based cohort study

AU - Bazo-Alvarez, Juan Carlos

AU - Morris, Tim P.

AU - Carpenter, James R.

AU - Hayes, Joseph F.

AU - Petersen, Irene

PY - 2020/1

Y1 - 2020/1

N2 - Background: Antipsychotics are often prescribed for long-term periods, however, most evidence of their impact on body weight comes from short-term clinical trials. Particularly, impact associated with dosage has been barely studied. Aims: The aim of this study was to describe the short- and long-term change in body weight of people initiated on high or low doses of the three most commonly prescribed second-generation antipsychotics. Methods: Retrospective cohorts of individuals with a diagnosed psychotic disorder observed from 2005 to 2015 in the UK primary care. The exposure was the first prescription of olanzapine, quetiapine or risperidone. The main outcome was change in body weight four years before and four years after initiation of antipsychotic treatment, stratified on sex and ‘low’ or ‘high’ dose. Results: In total, 22,306 women and 16,559 men were observed. Olanzapine treatment was associated with the highest change in weight, with higher doses resulting in more weight gain. After 4 years, given a high dose of olanzapine (> 5 mg), women gained on average +6.1 kg; whereas given a low dose (⩽ 5 mg), they gained +4.4 kg. During the first six weeks of olanzapine treatment, they gained on average +3.2 kg on high dose and +1.9 kg on low dose. The trends were similar for men. Individuals prescribed risperidone and quetiapine experienced less weight gain in both the short- and long-term. Conclusions: Olanzapine treatment was associated with the highest increase in weight. Higher doses were associated with more weight gain. Doctors should prescribe the lowest effective dose to balance mental-health benefits, weight gain and other adverse effects.

AB - Background: Antipsychotics are often prescribed for long-term periods, however, most evidence of their impact on body weight comes from short-term clinical trials. Particularly, impact associated with dosage has been barely studied. Aims: The aim of this study was to describe the short- and long-term change in body weight of people initiated on high or low doses of the three most commonly prescribed second-generation antipsychotics. Methods: Retrospective cohorts of individuals with a diagnosed psychotic disorder observed from 2005 to 2015 in the UK primary care. The exposure was the first prescription of olanzapine, quetiapine or risperidone. The main outcome was change in body weight four years before and four years after initiation of antipsychotic treatment, stratified on sex and ‘low’ or ‘high’ dose. Results: In total, 22,306 women and 16,559 men were observed. Olanzapine treatment was associated with the highest change in weight, with higher doses resulting in more weight gain. After 4 years, given a high dose of olanzapine (> 5 mg), women gained on average +6.1 kg; whereas given a low dose (⩽ 5 mg), they gained +4.4 kg. During the first six weeks of olanzapine treatment, they gained on average +3.2 kg on high dose and +1.9 kg on low dose. The trends were similar for men. Individuals prescribed risperidone and quetiapine experienced less weight gain in both the short- and long-term. Conclusions: Olanzapine treatment was associated with the highest increase in weight. Higher doses were associated with more weight gain. Doctors should prescribe the lowest effective dose to balance mental-health benefits, weight gain and other adverse effects.

KW - Antipsychotic agents

KW - dopamine

KW - electronic health records

KW - interrupted time series analysis

KW - noradrenaline

KW - serotonin

KW - weight gain

UR - http://www.scopus.com/inward/record.url?scp=85075119966&partnerID=8YFLogxK

U2 - 10.1177/0269881119885918

DO - 10.1177/0269881119885918

M3 - Journal article

C2 - 31724905

AN - SCOPUS:85075119966

VL - 34

SP - 79

EP - 85

JO - Journal of Psychopharmacology

JF - Journal of Psychopharmacology

SN - 0269-8811

IS - 1

ER -